{"name":"Aurobindo Pharma","slug":"aurobindo","ticker":"AUROPHARMA.NS","exchange":"NSE","domain":"aurobindo.com","description":"Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca.\n","hq":"Hyderabad, India","founded":0,"employees":"27707","ceo":"K. Nithyananda Reddy","sector":"Generics / APIs / Biosimilars","stockPrice":1510.9,"stockChange":13.4,"stockChangePercent":0.89,"marketCap":"$9.2B","metrics":{"revenue":3465106632.0879617,"revenueGrowth":8.4,"grossMargin":58,"rdSpend":0,"netIncome":364135354.94375014,"cash":928614307.1894077,"dividendYield":0.27,"peRatio":25.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-06-30","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV-1-infection)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-23","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV, HIV Infections)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-01","label":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Phase 3 readout (Type 2 Diabetes)","drug":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","drugSlug":"dapagliflozin-metformin-hydrochloride","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-02-28","label":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Phase 3 readout (Diabetes Mellitus, Type 2)","drug":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","drugSlug":"dapagliflozin-metformin-hydrochloride","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-08-01","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV-1-Infection)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Lisinopril patent cliff ($1.4B at risk)","drug":"Lisinopril","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Atorvastatin patent cliff ($2.5B at risk)","drug":"Atorvastatin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","genericName":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","slug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","indication":"Other","status":"marketed"},{"name":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","genericName":"DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE","slug":"dapagliflozin-metformin-hydrochloride","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Amphotericin B Liposome","genericName":"Amphotericin B Liposome","slug":"amphotericin-b-liposome","indication":"Infectious Disease","status":"marketed"}]}],"pipeline":[{"name":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","genericName":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","slug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Amphotericin B Liposome","genericName":"Amphotericin B Liposome","slug":"amphotericin-b-liposome","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","genericName":"DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE","slug":"dapagliflozin-metformin-hydrochloride","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Aurobindo Pharma reports 14% rise in Q3 FY24 net profit","summary":"Aurobindo Pharma's net profit rose 14% to ₹1,144 crore in the third quarter of FY24, driven by strong sales growth.","drugName":"","sentiment":"positive"},{"date":"2023-11-16","type":"deal","headline":"Aurobindo Pharma acquires US-based pharmaceutical company","summary":"Aurobindo Pharma has acquired a US-based pharmaceutical company, expanding its presence in the US market.","drugName":"","sentiment":"neutral"},{"date":"2023-08-25","type":"regulatory","headline":"FDA approves Aurobindo Pharma's generic version of Eliquis","summary":"The US FDA has approved Aurobindo Pharma's generic version of Eliquis, a blood thinner used to prevent stroke and blood clots.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZFdOdE1XdWVaSkhnbzhNbnNabF9uazJMeFAtLVNmOEZkaWprUDJJNTJWVmQ1UTVyc21jbzNDQ2t5a0tTMlpOWmF1MmdLaTNxN0NXU01GNWozMzFaNFRPM1h0dTFwdVVjbXExY2REcnhoTUN3Qk5XbHV4LXFIc3VVMHNIN2d2bFJGcFFYWE9QSENBdGtnUDlqUjA5b3NpMHRRTWJmZV9vNDliS3M?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance","summary":"How The Aurobindo Pharma (NSEI:AUROPHARMA) Valuation Story Is Shifting Around Margins And Risk - Yahoo Finance","headline":"How The Aurobindo Pharma (NSEI:AUROPHARMA) Valuation Story Is Shifting Around Margins And Risk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPa2xqUks4Y0MwU0staDZzVlQzM0VneUlIRzMxV1RiX3FlN3VNYjNFcGFtbjZuTW1EQldSQ3RXS1NzNk43LWZCV1FnVldQbWZVRGhMNEtBVFFSc242RXNZS0xnSXQzby1aZWFzWWZJMTVmdm9wTHBZWnJhUkVGcFBTMkRPaWdaZndzaFVNcExCUGEwQU5UTGRwdlBkLWxJd21vbDRvR094empNaU1rZDM3ZjlvbjZUMjlDUDZkRzdyX0c?oc=5","date":"2026-04-06","type":"deal","source":"meyka.com","summary":"Aurobindo Pharma Announces Share Buyback at ₹1,475 – Details on Size, Record Date, and More - meyka.com","headline":"Aurobindo Pharma Announces Share Buyback at ₹1,475 – Details on Size, Record Date, and More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZ1FTRzljbGpUVDBLcnprS3owb0JDNHNFdGtGdzJZTVpQak1idmpuSDBEazZFejZKSDZ0WndPak5DNnRZREU0UXcxclk3SjZiZm9xNWdBcmRvT3ItRWEwTnpqcGZSNnAtRXk2VVdZeFV6Yk9fRVVMY0lXczl3UjJ2bzdWYndDejA?oc=5","date":"2025-09-11","type":"patent","source":"Yahoo Finance UK","summary":"Private equity firm Advent to sell generic drugmaker Zentiva to GTCR - Yahoo Finance UK","headline":"Private equity firm Advent to sell generic drugmaker Zentiva to GTCR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRUlpSFJqX1JGdXlXUmdyVjdxVlB6V0thNU9XcmdNVlp0Qkpxa244SU9VNGdDcDhISno4YjBMSkRPbGxvWDYwWjNmQm9ta3ZSMDJBMFd0OVFSRzBQR1lkOU1mVGhJclgwQVk1ZjhTNTJiaW9TMHFoVnVYWWJPSFJkZjl3NjFsZ2txVFQ0?oc=5","date":"2025-08-19","type":"deal","source":"Yahoo Finance Singapore","summary":"India's Aurobindo Pharma leads race to buy generic drugmaker Zentiva for $5.5 billion, Economic Times reports - Yahoo Finance Singapore","headline":"India's Aurobindo Pharma leads race to buy generic drugmaker Zentiva for $5.5 billion, Economic Times reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBOLWU3bm1SMXZvTkNFcEd1RTFRMHBaR3AzMTdWUk5JY1BIaEdJR1J4dDN5c2FFWGo0a00tWlMyR3RJWUxidF92dFd1Y0xOX2ktZmxwb2otLVZycmJBNlZDRTktRlhUVjdodGc?oc=5","date":"2018-02-03","type":"pipeline","source":"Yahoo Finance UK","summary":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) income statement - Yahoo Finance UK","headline":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) income statement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE52Rmh5MGJHY1BQSm92dG9xSDFoQ0xXQ3diekY5Q054YjEwQUlfWEFOOVFXaXB2cFV3UEF2dGI1UzJRcl9NUllwdFMyYVFLWjZOYnBZUlUwNE1ZSE1kSlE?oc=5","date":"2017-06-15","type":"pipeline","source":"Yahoo Finance Australia","summary":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE44YlBfNU9saEFFLTNUZFl0TmpMNDZyeGxyUUlDbG5BZHJvVHlpNFZhNW9iQjk1TEVyMHgtdEZzRERxeWtEbXJweGRQWS1mT3FLWFR1cEhBNHk?oc=5","date":"2017-06-05","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Biocon Limited (BIOCON.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Biocon Limited (BIOCON.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFA3WVMyQlFOU3BRNndJeHAwTVZQbjRsajAwN3BSamVKX2g4MTBHY3FIbmxVblJDTS1kVksxVUtld3R6bllJck5uWTdpZ0VRLTZjZEFnMmdfaw?oc=5","date":"2017-05-31","type":"pipeline","source":"Yahoo Finance Australia","summary":"Lupin Limited (LUPIN.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Lupin Limited (LUPIN.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5WaFE1b1VXbThOZUVsM2ZDN1dtZ0lLSk9sTGV4eE1McnhzOGpYQ3NzUjZrUXdzZWtCQ0dRdUwyMEZ5T1BKanI2SFJmMC1iMzBwLUg4Smg4OA?oc=5","date":"2017-05-31","type":"pipeline","source":"Yahoo Finance Australia","summary":"Cipla Limited (CIPLA.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Cipla Limited (CIPLA.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9mWC1hMFBqbkFZaTRfNm9mYkNvOVRDS1VTbVNjREdZcDFjcS1UQUY0dFUwc1VlWVZuSl9kQkRsOTIzWjNjejlPTTBZSlNrU1FrTlQ5X3ZOeW84TVk?oc=5","date":"2017-05-23","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Glenmark Pharmaceuticals Limited (GLENMARK.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Lisinopril","drugSlug":"lisinopril","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Atorvastatin","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sun Pharma","Cipla","Dr. Reddy's Laboratories"],"therapeuticFocus":["Cardiovascular","Central Nervous System","Oncology"],"financials":{"source":"yahoo_finance","revenue":3276747201.3262,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":3276747201.3262},{"period":"2024-03-31","value":2997546062.83},{"period":"2023-03-31","value":2570711251.1862},{"period":"2022-03-31","value":2440116008.097}],"grossProfit":1841751323.5614,"grossProfitHistory":[{"period":"2025-03-31","value":1841751323.5614},{"period":"2024-03-31","value":1615318566.3646},{"period":"2023-03-31","value":1328052473.5082},{"period":"2022-03-31","value":1310711203.0038}],"rdSpend":9931078.074000001,"rdSpendHistory":[{"period":"2025-03-31","value":9931078.074000001},{"period":"2024-03-31","value":7897869.9762},{"period":"2023-03-31","value":4125940.0074},{"period":"2022-03-31","value":6812865.7576}],"sgaSpend":261321020.8534,"operatingIncome":527157497.1844,"operatingIncomeHistory":[{"period":"2025-03-31","value":527157497.1844},{"period":"2024-03-31","value":463818940.0422},{"period":"2023-03-31","value":264995833.024},{"period":"2022-03-31","value":344639737.4898}],"netIncome":364022570.3112,"netIncomeHistory":[{"period":"2025-03-31","value":364022570.3112},{"period":"2024-03-31","value":331346086.1878},{"period":"2023-03-31","value":201284468.85},{"period":"2022-03-31","value":276540319.681}],"eps":59.81,"epsHistory":[{"period":"2025-03-31","value":59.81},{"period":"2024-03-31","value":54.16},{"period":"2023-03-31","value":32.9},{"period":"2022-03-31","value":45.19}],"cash":581552862.673,"cashHistory":[{"period":"2025-03-31","value":581552862.673},{"period":"2024-03-31","value":354373447.1352},{"period":"2023-03-31","value":459094629.08460003},{"period":"2022-03-31","value":434681512.0274}],"totalAssets":5198931903.0678005,"totalLiabilities":1789686785.2296,"totalDebt":862872840.0138,"equity":3409912411.0968,"operatingCashflow":409839196.9588,"operatingCashflowHistory":[{"period":"2025-03-31","value":409839196.9588},{"period":"2024-03-31","value":254231421.5848},{"period":"2023-03-31","value":249242908.445},{"period":"2022-03-31","value":523859669.1552}],"capex":-263110912.317,"capexHistory":[{"period":"2025-03-31","value":-263110912.317},{"period":"2024-03-31","value":-371919396.01},{"period":"2023-03-31","value":-284085223.896},{"period":"2022-03-31","value":-282439442.7136}],"freeCashflow":146728284.64180002,"dividendsPaid":-108604.8496,"buybacks":-97142860.8576,"employees":27707,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":149466379.9846,"ebitda":197997083.5948,"period":"2025-12-31","revenue":898549533.1074001,"epsBasic":15.67,"netIncome":95059527.4446,"rdExpense":null,"epsDiluted":15.67,"grossProfit":535014640.342,"operatingIncome":136655184.8414},{"sga":null,"ebit":136231208.217,"ebitda":178597542.335,"period":"2025-06-30","revenue":813676931.6998,"epsBasic":14.2,"netIncome":86126778.565,"rdExpense":null,"epsDiluted":14.2,"grossProfit":475412507.737,"operatingIncome":125075192.7528},{"sga":null,"ebit":149672102.6324,"ebitda":190003140.09780002,"period":"2025-03-31","revenue":875221420.2688,"epsBasic":null,"netIncome":94347330.2578,"rdExpense":null,"epsDiluted":null,"grossProfit":442560585.0104,"operatingIncome":150326864.5622},{"sga":null,"ebit":137670222.4742,"ebitda":181376364.4964,"period":"2024-12-31","revenue":824263815.9810001,"epsBasic":14.56,"netIncome":88326026.7694,"rdExpense":null,"epsDiluted":14.56,"grossProfit":478043042.5076,"operatingIncome":126282377.4272},{"sga":null,"ebit":137861325.2384,"ebitda":177781961.6856,"period":"2024-09-30","revenue":798476429.8654,"epsBasic":14,"netIncome":85357146.1212,"rdExpense":null,"epsDiluted":14,"grossProfit":463235188.9756,"operatingIncome":123627824.2764}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1510.9,"previousClose":1497.5,"fiftyTwoWeekHigh":1525.9,"fiftyTwoWeekLow":1016.1,"fiftyTwoWeekRange":"1016.1 - 1525.9","fiftyDayAverage":1353.58,"twoHundredDayAverage":1195.57,"beta":0.03,"enterpriseValue":8968931812.980293,"forwardPE":19.8,"priceToBook":2.5,"priceToSales":2.64,"enterpriseToRevenue":2.59,"enterpriseToEbitda":12.85,"pegRatio":0,"ebitda":698184827.3669243,"ebitdaMargin":20.1,"freeCashflow":0,"operatingCashflow":0,"totalDebt":813962061.5352647,"debtToEquity":22.2,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":27,"targetMeanPrice":1393.63,"targetHighPrice":1662,"targetLowPrice":1020,"dividendRate":4,"payoutRatio":0.07,"fiveYearAvgDividendYield":0.65,"exDividendDate":1754611200,"insiderHeldPercent":54.2,"institutionHeldPercent":29,"sharesOutstanding":580801623,"floatShares":279000690,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":60.05,"epsForward":76.42,"revenuePerShare":571.32,"bookValue":603.39,"officers":[{"age":67,"name":"Mr. Kambam Nithyananda Reddy","title":"Vice Chairman & MD"},{"age":65,"name":"Mr. Mettu Madan Mohan Reddy","title":"Whole-Time Director"},{"age":44,"name":"Dr. Makkapati  Satakarni B.E., M.B.A., Ph.D.","title":"President of Biologics, CEO of Biologics, Vaccines and Peptid & Director"},{"age":64,"name":"Mr. Santhanam  Subramanian","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Mula Surya Narayana Murthy","title":"Senior Vice President of Accounts"},{"age":59,"name":"Dr. S. Vijaya Kumar","title":"President of Technical"},{"age":54,"name":"Dr. Parveen Kumar Luthra","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Ilapakurty S R . Chandra Rao","title":"Senior Vice President of Admin"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.aurobindo.com","phone":"91 40 6672 5000"}}